NSCLC Archive | IOZK

A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

2020-03-17/in Hyperthermia, International Publications, NSCLC /von 2020-03-17 / J Adv Res 2020 Jul;24:175-182

Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape

2019-06-21/in Dendritic Cells, International Publications, NSCLC /von 2019-06-21 / J. Cell. Physiol. 2020 Jan;235(1):74-86

Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.

2019-06-02/in Dendritic Cells, International Publications, NSCLC /von 2019-06-02 / J Clin Oncol 37, 2019 (suppl; abstr 9039)

Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.

2019-05-31/in Dendritic Cells, NSCLC /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)

Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer

2019-04-20/in Hyperthermia, International Publications, NSCLC /von 2019-04-20 / Chin. Med. J. 2019 Apr;132(8):922-927

[Vaccines for the treatment of non-small cell lung cancer]

2019-03-20/in Dendritic Cells, International Publications, NSCLC /von 2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-425

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients‘ preference-based study (PPPS)

2018-10-29/in Dendritic Cells, International Publications, NSCLC /von 2018-10-29 / Clin Transl Oncol 2019 Jun;21(6):721-728

Recombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways

2018-09-23/in Dendritic Cells, International Publications, NSCLC /von 2018-09-23 / Thorac Cancer 2018 Nov;9(11):1437-1452

Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.

2018-06-03/in Dendritic Cells, NSCLC /von 2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)

Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

2017-12-21/in Dendritic Cells, International Publications, NSCLC /von 2017-12-21 / BMC Cancer 2017 12;17(1):884